Titre : Vibrio

Vibrio : Questions médicales fréquentes

Termes MeSH sélectionnés :

Managed Care Programs

Questions fréquentes et termes MeSH associés

Diagnostic 5

#1

Comment diagnostiquer une infection à Vibrio ?

Le diagnostic repose sur des cultures bactériennes à partir d'échantillons de selles.
Vibrio Infections bactériennes
#2

Quels tests sont utilisés pour identifier Vibrio ?

Des tests de culture et des tests biochimiques spécifiques sont utilisés.
Tests de laboratoire Vibrio
#3

Les tests sérologiques sont-ils utiles ?

Les tests sérologiques ne sont généralement pas utilisés pour Vibrio.
Tests sérologiques Vibrio
#4

Peut-on diagnostiquer Vibrio par PCR ?

Oui, la PCR peut être utilisée pour détecter l'ADN de Vibrio dans les échantillons.
PCR Vibrio
#5

Quels symptômes orientent vers un diagnostic de Vibrio ?

Des symptômes gastro-intestinaux comme la diarrhée aiguë peuvent indiquer une infection.
Diarrhée Vibrio

Symptômes 5

#1

Quels sont les symptômes d'une infection à Vibrio ?

Les symptômes incluent diarrhée, vomissements, douleurs abdominales et fièvre.
Symptômes Vibrio
#2

La diarrhée est-elle toujours présente ?

Non, la diarrhée est fréquente mais pas systématique dans les infections à Vibrio.
Diarrhée Vibrio
#3

Les infections à Vibrio causent-elles de la fièvre ?

Oui, la fièvre peut accompagner les infections à Vibrio, mais ce n'est pas toujours le cas.
Fièvre Vibrio
#4

Y a-t-il des symptômes graves associés ?

Des symptômes graves peuvent inclure déshydratation et choc septique dans les cas sévères.
Choc septique Vibrio
#5

Les symptômes apparaissent-ils rapidement ?

Les symptômes peuvent apparaître rapidement, souvent dans les 24 heures suivant l'infection.
Infection Vibrio

Prévention 5

#1

Comment prévenir les infections à Vibrio ?

Évitez de consommer des fruits de mer crus ou mal cuits et lavez-vous les mains.
Prévention Vibrio
#2

Le lavage des mains est-il important ?

Oui, le lavage des mains réduit le risque d'infection par Vibrio et d'autres pathogènes.
Hygiène Vibrio
#3

Les vaccinations existent-elles contre Vibrio ?

Actuellement, il n'existe pas de vaccin efficace contre les infections à Vibrio.
Vaccins Vibrio
#4

Faut-il éviter certains aliments ?

Oui, évitez les fruits de mer crus, surtout en période de chaleur ou d'épidémies.
Alimentation Vibrio
#5

Les voyages augmentent-ils le risque d'infection ?

Oui, voyager dans des zones où Vibrio est endémique augmente le risque d'infection.
Voyages Vibrio

Traitements 5

#1

Quel est le traitement principal pour Vibrio ?

Le traitement principal est la réhydratation, souvent accompagnée d'antibiotiques si nécessaire.
Traitement Vibrio
#2

Quels antibiotiques sont efficaces contre Vibrio ?

Des antibiotiques comme la doxycycline et l'azithromycine sont souvent utilisés.
Antibiotiques Vibrio
#3

La réhydratation est-elle toujours nécessaire ?

Oui, la réhydratation est cruciale, surtout en cas de diarrhée sévère.
Réhydratation Vibrio
#4

Les traitements sont-ils différents selon le type de Vibrio ?

Oui, le traitement peut varier selon le type de Vibrio et la gravité de l'infection.
Types de Vibrio Traitement
#5

Les probiotiques aident-ils dans le traitement ?

Les probiotiques peuvent aider à restaurer la flore intestinale, mais ne remplacent pas le traitement.
Probiotiques Vibrio

Complications 5

#1

Quelles complications peuvent survenir avec Vibrio ?

Les complications incluent la déshydratation sévère, le choc septique et l'insuffisance rénale.
Complications Vibrio
#2

La déshydratation est-elle une complication fréquente ?

Oui, la déshydratation est une complication courante, surtout en cas de diarrhée sévère.
Déshydratation Vibrio
#3

Les infections à Vibrio peuvent-elles être mortelles ?

Oui, dans les cas graves, les infections à Vibrio peuvent être mortelles sans traitement rapide.
Mortalité Vibrio
#4

Y a-t-il des risques pour les personnes immunodéprimées ?

Oui, les personnes immunodéprimées sont à risque accru de complications graves.
Immunodépression Vibrio
#5

Les infections cutanées sont-elles possibles ?

Oui, Vibrio peut causer des infections cutanées, surtout après des blessures en milieu aquatique.
Infections cutanées Vibrio

Facteurs de risque 5

#1

Quels sont les principaux facteurs de risque pour Vibrio ?

Les principaux facteurs incluent la consommation de fruits de mer crus et l'immunodépression.
Facteurs de risque Vibrio
#2

Les personnes âgées sont-elles plus à risque ?

Oui, les personnes âgées ont un risque accru de complications graves liées à Vibrio.
Personnes âgées Vibrio
#3

Le diabète augmente-t-il le risque d'infection ?

Oui, le diabète peut augmenter le risque d'infections graves à Vibrio.
Diabète Vibrio
#4

Les personnes vivant près de l'eau sont-elles plus exposées ?

Oui, elles peuvent être plus exposées aux infections à Vibrio, surtout en été.
Exposition Vibrio
#5

Les voyages dans des zones endémiques sont-ils risqués ?

Oui, voyager dans des zones où Vibrio est courant augmente le risque d'infection.
Voyages Vibrio
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Vibrio : Questions médicales les plus fréquentes", "headline": "Vibrio : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Vibrio : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-05", "dateModified": "2025-04-30", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Vibrio" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Vibrionaceae", "url": "https://questionsmedicales.fr/mesh/D014737", "about": { "@type": "MedicalCondition", "name": "Vibrionaceae", "code": { "@type": "MedicalCode", "code": "D014737", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B03.660.250.830" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Vibrio alginolyticus", "alternateName": "Vibrio alginolyticus", "url": "https://questionsmedicales.fr/mesh/D044149", "about": { "@type": "MedicalCondition", "name": "Vibrio alginolyticus", "code": { "@type": "MedicalCode", "code": "D044149", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B03.660.250.830.830.030" } } }, { "@type": "MedicalWebPage", "name": "Vibrio cholerae", "alternateName": "Vibrio cholerae", "url": "https://questionsmedicales.fr/mesh/D014734", "about": { "@type": "MedicalCondition", "name": "Vibrio cholerae", "code": { "@type": "MedicalCode", "code": "D014734", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B03.660.250.830.830.100" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Vibrio cholerae non-O1", "alternateName": "Vibrio cholerae non-O1", "url": "https://questionsmedicales.fr/mesh/D044163", "about": { "@type": "MedicalCondition", "name": "Vibrio cholerae non-O1", "code": { "@type": "MedicalCode", "code": "D044163", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B03.660.250.830.830.100.075" } } }, { "@type": "MedicalWebPage", "name": "Vibrio cholerae O1", "alternateName": "Vibrio cholerae O1", "url": "https://questionsmedicales.fr/mesh/D041241", "about": { "@type": "MedicalCondition", "name": "Vibrio cholerae O1", "code": { "@type": "MedicalCode", "code": "D041241", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B03.660.250.830.830.100.151" } } }, { "@type": "MedicalWebPage", "name": "Vibrio cholerae O139", "alternateName": "Vibrio cholerae O139", "url": "https://questionsmedicales.fr/mesh/D041242", "about": { "@type": "MedicalCondition", "name": "Vibrio cholerae O139", "code": { "@type": "MedicalCode", "code": "D041242", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B03.660.250.830.830.100.200" } } } ] }, { "@type": "MedicalWebPage", "name": "Vibrio mimicus", "alternateName": "Vibrio mimicus", "url": "https://questionsmedicales.fr/mesh/D044164", "about": { "@type": "MedicalCondition", "name": "Vibrio mimicus", "code": { "@type": "MedicalCode", "code": "D044164", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B03.660.250.830.830.500" } } }, { "@type": "MedicalWebPage", "name": "Vibrio parahaemolyticus", "alternateName": "Vibrio parahaemolyticus", "url": "https://questionsmedicales.fr/mesh/D014736", "about": { "@type": "MedicalCondition", "name": "Vibrio parahaemolyticus", "code": { "@type": "MedicalCode", "code": "D014736", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B03.660.250.830.830.590" } } }, { "@type": "MedicalWebPage", "name": "Vibrio vulnificus", "alternateName": "Vibrio vulnificus", "url": "https://questionsmedicales.fr/mesh/D041261", "about": { "@type": "MedicalCondition", "name": "Vibrio vulnificus", "code": { "@type": "MedicalCode", "code": "D041261", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B03.660.250.830.830.900" } } } ], "about": { "@type": "MedicalCondition", "name": "Vibrio", "alternateName": "Vibrio", "code": { "@type": "MedicalCode", "code": "D014733", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Jaime Martinez-Urtaza", "url": "https://questionsmedicales.fr/author/Jaime%20Martinez-Urtaza", "affiliation": { "@type": "Organization", "name": "Department of Genetics and Microbiology, Universitat Autònoma de Barcelona, Barcelona, Spain." } }, { "@type": "Person", "name": "Jessica L Jones", "url": "https://questionsmedicales.fr/author/Jessica%20L%20Jones", "affiliation": { "@type": "Organization", "name": "U.S. Food and Drug Administration Gulf Coast Seafood Laboratory 1 Iberville Drive UNITED STATES Dauphin Island AL 36528 2514068136." } }, { "@type": "Person", "name": "William C Walton", "url": "https://questionsmedicales.fr/author/William%20C%20Walton", "affiliation": { "@type": "Organization", "name": "2Auburn University Shellfish Laboratory, School of Fisheries, Aquaculture, and Aquatic Sciences, Auburn University, 150 Agassiz Street, Dauphin Island, AL 36528, USA." } }, { "@type": "Person", "name": "Julia C van Kessel", "url": "https://questionsmedicales.fr/author/Julia%20C%20van%20Kessel", "affiliation": { "@type": "Organization", "name": "Biology Department, Indiana University, Bloomington, Indiana, USA jcvk@indiana.edu." } }, { "@type": "Person", "name": "Blake Ushijima", "url": "https://questionsmedicales.fr/author/Blake%20Ushijima", "affiliation": { "@type": "Organization", "name": "Carlson College of Veterinary Medicine, Oregon State University, Corvallis, OR, United States of America." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "The Impact of a Primary Care Telepsychiatry Program on Outcomes of Managed Care Older Adults.", "datePublished": "2022-11-07", "url": "https://questionsmedicales.fr/article/36356654", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jamda.2022.10.004" } }, { "@type": "ScholarlyArticle", "name": "The Influence of National Standards on Medicaid Managed Care Programs: Implications for Children and Youth with Special Health Care Needs.", "datePublished": "2022-08-23", "url": "https://questionsmedicales.fr/article/35999481", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s10995-022-03499-y" } }, { "@type": "ScholarlyArticle", "name": "Asthma outcomes in pediatric patients with 30-day follow-up after an asthma hospitalization in a Medicaid-managed care program.", "datePublished": "2023-03-21", "url": "https://questionsmedicales.fr/article/36893220", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/02770903.2023.2185155" } }, { "@type": "ScholarlyArticle", "name": "Dyslipidemia treatment and attainment of LDL-cholesterol treatment goals in patients participating in the Managed Care for Acute Myocardial Infarction Survivors program.", "datePublished": "2023-03-05", "url": "https://questionsmedicales.fr/article/36871294", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.33963/KP.a2023.0045" } }, { "@type": "ScholarlyArticle", "name": "The long-term benefit of a cardiac rehabilitation program after myocardial infarction in patients under the Managed Care for Acute Myocardial Infarction Survivors (MACAMIS) program in Poland: A single-center study.", "datePublished": "2022-09-07", "url": "https://questionsmedicales.fr/article/36069197", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.33963/KP.a2022.0207" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Bactéries", "item": "https://questionsmedicales.fr/mesh/D001419" }, { "@type": "ListItem", "position": 3, "name": "Proteobacteria", "item": "https://questionsmedicales.fr/mesh/D020560" }, { "@type": "ListItem", "position": 4, "name": "Gammaproteobacteria", "item": "https://questionsmedicales.fr/mesh/D020563" }, { "@type": "ListItem", "position": 5, "name": "Vibrionaceae", "item": "https://questionsmedicales.fr/mesh/D014737" }, { "@type": "ListItem", "position": 6, "name": "Vibrio", "item": "https://questionsmedicales.fr/mesh/D014733" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Vibrio - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Vibrio", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-17", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Vibrio", "description": "Comment diagnostiquer une infection à Vibrio ?\nQuels tests sont utilisés pour identifier Vibrio ?\nLes tests sérologiques sont-ils utiles ?\nPeut-on diagnostiquer Vibrio par PCR ?\nQuels symptômes orientent vers un diagnostic de Vibrio ?", "url": "https://questionsmedicales.fr/mesh/D014733?mesh_terms=Managed+Care+Programs#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Vibrio", "description": "Quels sont les symptômes d'une infection à Vibrio ?\nLa diarrhée est-elle toujours présente ?\nLes infections à Vibrio causent-elles de la fièvre ?\nY a-t-il des symptômes graves associés ?\nLes symptômes apparaissent-ils rapidement ?", "url": "https://questionsmedicales.fr/mesh/D014733?mesh_terms=Managed+Care+Programs#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Vibrio", "description": "Comment prévenir les infections à Vibrio ?\nLe lavage des mains est-il important ?\nLes vaccinations existent-elles contre Vibrio ?\nFaut-il éviter certains aliments ?\nLes voyages augmentent-ils le risque d'infection ?", "url": "https://questionsmedicales.fr/mesh/D014733?mesh_terms=Managed+Care+Programs#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Vibrio", "description": "Quel est le traitement principal pour Vibrio ?\nQuels antibiotiques sont efficaces contre Vibrio ?\nLa réhydratation est-elle toujours nécessaire ?\nLes traitements sont-ils différents selon le type de Vibrio ?\nLes probiotiques aident-ils dans le traitement ?", "url": "https://questionsmedicales.fr/mesh/D014733?mesh_terms=Managed+Care+Programs#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Vibrio", "description": "Quelles complications peuvent survenir avec Vibrio ?\nLa déshydratation est-elle une complication fréquente ?\nLes infections à Vibrio peuvent-elles être mortelles ?\nY a-t-il des risques pour les personnes immunodéprimées ?\nLes infections cutanées sont-elles possibles ?", "url": "https://questionsmedicales.fr/mesh/D014733?mesh_terms=Managed+Care+Programs#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Vibrio", "description": "Quels sont les principaux facteurs de risque pour Vibrio ?\nLes personnes âgées sont-elles plus à risque ?\nLe diabète augmente-t-il le risque d'infection ?\nLes personnes vivant près de l'eau sont-elles plus exposées ?\nLes voyages dans des zones endémiques sont-ils risqués ?", "url": "https://questionsmedicales.fr/mesh/D014733?mesh_terms=Managed+Care+Programs#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une infection à Vibrio ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des cultures bactériennes à partir d'échantillons de selles." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour identifier Vibrio ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de culture et des tests biochimiques spécifiques sont utilisés." } }, { "@type": "Question", "name": "Les tests sérologiques sont-ils utiles ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les tests sérologiques ne sont généralement pas utilisés pour Vibrio." } }, { "@type": "Question", "name": "Peut-on diagnostiquer Vibrio par PCR ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la PCR peut être utilisée pour détecter l'ADN de Vibrio dans les échantillons." } }, { "@type": "Question", "name": "Quels symptômes orientent vers un diagnostic de Vibrio ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes gastro-intestinaux comme la diarrhée aiguë peuvent indiquer une infection." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une infection à Vibrio ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent diarrhée, vomissements, douleurs abdominales et fièvre." } }, { "@type": "Question", "name": "La diarrhée est-elle toujours présente ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Non, la diarrhée est fréquente mais pas systématique dans les infections à Vibrio." } }, { "@type": "Question", "name": "Les infections à Vibrio causent-elles de la fièvre ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la fièvre peut accompagner les infections à Vibrio, mais ce n'est pas toujours le cas." } }, { "@type": "Question", "name": "Y a-t-il des symptômes graves associés ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes graves peuvent inclure déshydratation et choc septique dans les cas sévères." } }, { "@type": "Question", "name": "Les symptômes apparaissent-ils rapidement ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent apparaître rapidement, souvent dans les 24 heures suivant l'infection." } }, { "@type": "Question", "name": "Comment prévenir les infections à Vibrio ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Évitez de consommer des fruits de mer crus ou mal cuits et lavez-vous les mains." } }, { "@type": "Question", "name": "Le lavage des mains est-il important ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le lavage des mains réduit le risque d'infection par Vibrio et d'autres pathogènes." } }, { "@type": "Question", "name": "Les vaccinations existent-elles contre Vibrio ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de vaccin efficace contre les infections à Vibrio." } }, { "@type": "Question", "name": "Faut-il éviter certains aliments ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, évitez les fruits de mer crus, surtout en période de chaleur ou d'épidémies." } }, { "@type": "Question", "name": "Les voyages augmentent-ils le risque d'infection ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, voyager dans des zones où Vibrio est endémique augmente le risque d'infection." } }, { "@type": "Question", "name": "Quel est le traitement principal pour Vibrio ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement principal est la réhydratation, souvent accompagnée d'antibiotiques si nécessaire." } }, { "@type": "Question", "name": "Quels antibiotiques sont efficaces contre Vibrio ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Des antibiotiques comme la doxycycline et l'azithromycine sont souvent utilisés." } }, { "@type": "Question", "name": "La réhydratation est-elle toujours nécessaire ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la réhydratation est cruciale, surtout en cas de diarrhée sévère." } }, { "@type": "Question", "name": "Les traitements sont-ils différents selon le type de Vibrio ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le traitement peut varier selon le type de Vibrio et la gravité de l'infection." } }, { "@type": "Question", "name": "Les probiotiques aident-ils dans le traitement ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Les probiotiques peuvent aider à restaurer la flore intestinale, mais ne remplacent pas le traitement." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec Vibrio ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent la déshydratation sévère, le choc septique et l'insuffisance rénale." } }, { "@type": "Question", "name": "La déshydratation est-elle une complication fréquente ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la déshydratation est une complication courante, surtout en cas de diarrhée sévère." } }, { "@type": "Question", "name": "Les infections à Vibrio peuvent-elles être mortelles ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, dans les cas graves, les infections à Vibrio peuvent être mortelles sans traitement rapide." } }, { "@type": "Question", "name": "Y a-t-il des risques pour les personnes immunodéprimées ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes immunodéprimées sont à risque accru de complications graves." } }, { "@type": "Question", "name": "Les infections cutanées sont-elles possibles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, Vibrio peut causer des infections cutanées, surtout après des blessures en milieu aquatique." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque pour Vibrio ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les principaux facteurs incluent la consommation de fruits de mer crus et l'immunodépression." } }, { "@type": "Question", "name": "Les personnes âgées sont-elles plus à risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes âgées ont un risque accru de complications graves liées à Vibrio." } }, { "@type": "Question", "name": "Le diabète augmente-t-il le risque d'infection ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le diabète peut augmenter le risque d'infections graves à Vibrio." } }, { "@type": "Question", "name": "Les personnes vivant près de l'eau sont-elles plus exposées ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent être plus exposées aux infections à Vibrio, surtout en été." } }, { "@type": "Question", "name": "Les voyages dans des zones endémiques sont-ils risqués ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, voyager dans des zones où Vibrio est courant augmente le risque d'infection." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale


Validation scientifique effectuée le 30/04/2025

Contenu vérifié selon les dernières recommandations médicales

Auteurs principaux

Jaime Martinez-Urtaza

4 publications dans cette catégorie

Affiliations :
  • Department of Genetics and Microbiology, Universitat Autònoma de Barcelona, Barcelona, Spain.
Publications dans "Vibrio" :

Jessica L Jones

3 publications dans cette catégorie

Affiliations :
  • U.S. Food and Drug Administration Gulf Coast Seafood Laboratory 1 Iberville Drive UNITED STATES Dauphin Island AL 36528 2514068136.

William C Walton

3 publications dans cette catégorie

Affiliations :
  • 2Auburn University Shellfish Laboratory, School of Fisheries, Aquaculture, and Aquatic Sciences, Auburn University, 150 Agassiz Street, Dauphin Island, AL 36528, USA.

Julia C van Kessel

3 publications dans cette catégorie

Affiliations :
  • Biology Department, Indiana University, Bloomington, Indiana, USA jcvk@indiana.edu.
Publications dans "Vibrio" :

Blake Ushijima

2 publications dans cette catégorie

Affiliations :
  • Carlson College of Veterinary Medicine, Oregon State University, Corvallis, OR, United States of America.

Fazlurrahman Khan

2 publications dans cette catégorie

Affiliations :
  • Research Center for Marine Integrated Bionics Technology, Pukyong National University, Busan, 48513, South Korea.

Young-Mog Kim

2 publications dans cette catégorie

Affiliations :
  • Department of Food Science and Technology, Pukyong National University, Busan, 48513, South Korea. ymkim@pknu.ac.kr.
  • Research Center for Marine Integrated Bionics Technology, Pukyong National University, Busan, 48513, South Korea. ymkim@pknu.ac.kr.

Heidi A Butz

2 publications dans cette catégorie

Affiliations :
  • Department of Molecular Biosciences and LaMontagne Center for Infectious Diseases, The University of Texas at Austin, Austin, Texas, USA.
Publications dans "Vibrio" :

Alexandra R Mey

2 publications dans cette catégorie

Affiliations :
  • Department of Molecular Biosciences and LaMontagne Center for Infectious Diseases, The University of Texas at Austin, Austin, Texas, USA.
Publications dans "Vibrio" :

Ashley L Ciosek

2 publications dans cette catégorie

Affiliations :
  • Department of Molecular Biosciences and LaMontagne Center for Infectious Diseases, The University of Texas at Austin, Austin, Texas, USA.
Publications dans "Vibrio" :

Bryan W Davies

2 publications dans cette catégorie

Affiliations :
  • Department of Molecular Biosciences and LaMontagne Center for Infectious Diseases, The University of Texas at Austin, Austin, Texas, USA.

Shelley M Payne

2 publications dans cette catégorie

Affiliations :
  • Department of Molecular Biosciences and LaMontagne Center for Infectious Diseases, The University of Texas at Austin, Austin, Texas, USA payne@utexas.edu.
Publications dans "Vibrio" :

Craig Baker-Austin

2 publications dans cette catégorie

Affiliations :
  • International Centre of Excellence for Seafood Safety, Centre for Environment, Fisheries and Aquaculture Science, Weymouth, UK. Electronic address: craig.baker-austin@cefas.co.uk.
Publications dans "Vibrio" :

Joaquin Trinanes

2 publications dans cette catégorie

Affiliations :
  • Laboratory of Systems, Technological Research Institute, Universidad de Santiago de Compostela, Santiago de Compostela, Spain.
Publications dans "Vibrio" :

Shigeaki Matsuda

2 publications dans cette catégorie

Affiliations :
  • Department of Bacterial Infections, Research Institute for Microbial Diseases, Osaka University.
Publications dans "Vibrio" :

Chao Yang

2 publications dans cette catégorie

Affiliations :
  • State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, 100071, China.
Publications dans "Vibrio" :

Lin Yan

2 publications dans cette catégorie

Affiliations :
  • National Center for Food Safety Risk Assessment, Beijing, 100022, China.
Publications dans "Vibrio" :

Salvador Almagro-Moreno

2 publications dans cette catégorie

Affiliations :
  • Burnett School of Biomedical Sciences, University of Central Florida, Orlando, FL, USA. samoreno@ucf.edu.
  • National Center for Integrated Coastal Research, University of Central Florida, Orlando, FL, USA. samoreno@ucf.edu.
Publications dans "Vibrio" :

Orr H Shapiro

2 publications dans cette catégorie

Affiliations :
  • Department of Plant and Environmental Sciences, Weizmann Institute of Science, Rehovot, Israel. orr@agri.gov.il.
  • Department of Food Quality and Safety, Agricultural Research Organization, Volcani Center, Rishon LeZion, Israel. orr@agri.gov.il.
Publications dans "Vibrio" :

Victoria L Pruente

2 publications dans cette catégorie

Affiliations :
  • U.S. Food and Drug Administration, Division of Seafood Science and Technology, Gulf Coast Seafood Laboratory, 1 Iberville Drive, Dauphin Island, AL 36528, USA; Auburn University Shellfish Laboratory, School of Fisheries, Aquaculture, and Aquatic Sciences, Auburn University, 150 Agassiz Street, Dauphin Island, AL 36528, USA. Electronic address: vlp0006@auburn.edu.

Sources (10000 au total)

The Impact of a Primary Care Telepsychiatry Program on Outcomes of Managed Care Older Adults.

The goal of this study was to assess the outcomes of a primary-based telepsychiatry intervention program for older managed care enrollees with depression/anxiety and with limited access to in-person p... A pre-post design was used to examine service use (n = 218) and severity of depression (n = 204). Enrollment, claims, and depression and anxiety score data were obtained from the medical group. The im... The program was funded by the Senior Care Action Network (SCAN) group and implemented by a large medical group serving older adults who were identified as needing outpatient psychiatric care, includin... Poisson regressions were used to examine changes in predicted rates of outpatient services, emergency department visits, and hospitalizations up to 24 months prior and 24 months following the first te... The number of outpatient services declined significantly by 0.24 per patient per 6-month time frame following the first telepsychiatry visit. The number of emergency department visits and hospitalizat... The telepsychiatry program lowered service use, depression severity, and increased better access to psychiatry care. The findings highlight the potential benefits of sustaining and expanding the telep...

The Influence of National Standards on Medicaid Managed Care Programs: Implications for Children and Youth with Special Health Care Needs.

To improve services and assure predictable costs of care for Children and Youth with Special Health Care Needs (CYSHCN), state Title V and Medicaid programs are cooperating to reconceive care systems ... Data are drawn from a recent evaluation of the National Standards, which define the core components of a comprehensive, coordinated, and family-centered system of care for CYSHCN. The authors synthesi... The states used the National Standards in different ways. Florida translated the Standards into contract provisions and holds its MCO accountable to performance targets specific to CYSHCN. In Colorado... The National Standards offer a flexible framework to help states design Medicaid managed care programs and improve systems of care for CYSHCN. States can learn from one another's experiences applying ...

Asthma outcomes in pediatric patients with 30-day follow-up after an asthma hospitalization in a Medicaid-managed care program.

National asthma guidelines recommend an outpatient follow-up after hospitalization for asthma. Our aim is determine if a follow-up visit within 30 days after an asthma hospitalization impacts risk for... This was a retrospective cohort study of claims data of Texas Children's Health Plan (a Medicaid managed care program) members age 1 to <18 years and hospitalized for asthma between January 1, 2012, a... We identified 1,485 children age 1 to <18 years hospitalized for asthma. Comparing those with a 30 day follow-up to those without, there was no difference in days to re-hospitalization (adjusted hazar... Having a follow-up outpatient visit within 30 days of an asthma hospitalization is not associated with a decrease in asthma re-hospitalization or emergency department visit in the 30-365 day period fo...

Dyslipidemia treatment and attainment of LDL-cholesterol treatment goals in patients participating in the Managed Care for Acute Myocardial Infarction Survivors program.

Patients after acute myocardial infarction (AMI) are at very high cardiovascular (CV) risk. Therefore, appropriate management of dyslipidemia with adequate lipid-lowering therapy is crucial for preven... Our analysis aimed to assess the treatment of dyslipidemia and attainment of low-density lipoprotein cholesterol (LDL-C) treatment goals in patients after AMI who participated in the Managed Care for ... This study is a retrospective analysis of consecutive patients with AMI who agreed to participate and completed the 12-month MACAMIS program at one of three tertiary referral cardiovascular centers in... 1499 patients after AMI were enrolled in the study. High-intensity statin therapy was prescribed for 85.5% of analyzed patients on hospital discharge. Combined therapy with high-intensity statin and e... Our analysis suggests that participation in the managed care program might be associated with improved quality of dyslipidemia management in AMI patients. Nonetheless, only one-fifth of patients who c...

The long-term benefit of a cardiac rehabilitation program after myocardial infarction in patients under the Managed Care for Acute Myocardial Infarction Survivors (MACAMIS) program in Poland: A single-center study.

The Managed Care for Acute Myocardial Infarction Survivors (MACAMIS) program introduced for patients after myocardial infarction (MI) consists of 4 modules including early cardiac rehabilitation (CR).... We compared the impact of CR on survival of patients after MI included in the MACAMIS program.... Patients in MACAMIS were divided into subgroups based on being qualified or not qual-ified for CR and on whether they completed or failed to complete CR. We evaluated one-, two-, and three-year mortal... Of 244 patients in MACAMIS, 174 patients were qualified for CR. They were younger, had less advanced coronary artery disease (CAD), higher ejection fraction (EF), and fewer comorbidities. Finally, 102... Patients with MI in the MACAMIS program had better prognosis when participating in CR. After completing the MACAMIS program, increased mortality was observed in the following years. Despite the flexib...

Feasibility of hybrid telerehabilitation as a component of the Managed Care after Acute Myocardial Infarction (MC-AMI) program in a 12-month follow-up: experience from a single center.

Managed Care after Myocardial Infarction (MC‑AMI [KOS-Zawał]), a comprehensive care program dedicated to patients after myocardial infarction, was implemented in Poland in 2017. Hybrid cardiac telereh... We evaluated the feasibility of HTR as a component of MC‑AMI and assessed its safety and acceptance by patients. One‑year all‑cause mortality among the patients participating and not participating in ... The MC‑AMI group included 114 patients who underwent a 5‑week HTR program comprising telemonitored Nordic walking training sessions, and who completed the entire 12‑month MC‑AMI program. The influence... HTR significantly improved the functional capacity assessed in the stress test and was well‑received by the patients. In the study group, nonfatal non-ST‑segment elevation myocardial infarction, elect... HTR as a component of MC‑AMI was a feasible, safe, and well‑accepted form of cardiac rehabilitation. Participation in MC‑AMI including HTR was associated with a significantly lower risk of 1‑year all‑...

Managed Care after Acute Myocardial Infarction (MC-AMI) - Poland's nationwide program of comprehensive post-MI care improves prognosis in 2-year follow-up. A single high-volume center intention-to-treat analysis.

Managed Care in Acute Myocardial Infarction (MC-AMI) is a program introduced in Poland aimed at comprehensive, scheduled, and supervised care for AMI patients to improve longterm prognosis.... Our study aimed to compare 24-month mortality and the incidence of major cardiovascular events (MACE: a composite of death, recurrent MI, and hospitalization for heart failure) in a cohort of AMI pati... We analyzed 2323 consecutive patients with AMI: 1261 patients enrolled in the MC-AMI era (study group) and 1062 patients treated 12 months before the MC-AMI era (control group). In the study group, 57... Treatment in the MC-AMI era was related to a 30% reduction in all-cause mortality and a 14% reduction of MACE although it was not related to the reduction of hospitalization for heart failure (HF) or ... AMI treatment in the MC-AMI era reduces 24-month mortality and MACE. Moreover, AMI treatment in MC-AMI is inversely related to mortality, MACE, and hospitalization for HF. The effect is pronounced in ...

State-Level Variation in Medicaid Managed Care Enrollment and Specialty Care for Publicly Insured Children.

Medicaid and Children's Health Insurance Program cover almost 50% of children with special health care needs (CSHCN). CSHCN often require specialty services and have been increasingly enrolled in Medi... To provide recent, nationwide evidence on the association of MMC penetration with specialty care access among publicly insured children, with a special focus on CSHCN.... This cross-sectional study used nationally representative data from the 2016 to 2019 National Survey of Children's Health to identify publicly insured children in 41 states that administered comprehen... Form CMS-416 data were used to measure state-year level share of Medicaid-enrolled children who were covered by MMC (ie, MMC penetration).... Measures of specialty care access included whether, in the past year, the child had (1) any visit to non-mental health (MH) specialists, (2) any visit to MH professionals, and (3) any unmet health car... Among 20 029 publicly insured children, 7164 (35.8%) were CSHCN, 9537 (48.2%) were female, 4110 (37.2%) were caregiver-reported Hispanic, and 2812 (21.4%) were caregiver-reported non-Hispanic Black (a... In this cross-sectional study evaluating MMC and specialty care access for publicly insured children, increased MMC enrollment was not associated with improved specialty care access for publicly insur...

Medicaid Managed Care and Pediatric Dental Emergency Department Visits.

Millions of economically disadvantaged children depend on Medicaid for dental care, with states differing in whether they deliver these benefits using fee-for-service or capitated managed care payment... To estimate the association between the adoption of managed care for dental services in Florida's Medicaid program and nontraumatic dental emergency department visits and associated charges.... This cohort study used an event-study difference-in-differences design, leveraging Florida Medicaid's staggered adoption of managed care to examine its association with pediatric nontraumatic dental e... The county of residence transitioning Medicaid dental services from fee-for-service to a fully capitated managed care program managed by a dental plan.... The rate of nontraumatic dental emergency department visits per 100 000 pediatric Medicaid enrollees and the associated mean charges per visit. Nontraumatic dental emergency department visits are a we... Among the 34 414 pediatric nontraumatic dental emergency department visits that met inclusion criteria across Florida's 67 counties, the mean (SD) age of patients was 8.11 (5.28) years, and 50.8% of p... In this cohort study, Florida Medicaid's adoption of managed care for pediatric dental services was associated with increased emergency department visits for children, which could be associated with d...